Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Sep;56(9):2786-2797.
doi: 10.1161/STROKEAHA.125.050397. Epub 2025 Jun 26.

The Large Core Paradox

Affiliations
Review

The Large Core Paradox

Adrien Ter Schiphorst et al. Stroke. 2025 Sep.

Abstract

Recently, 6 randomized controlled trials of endovascular treatment (EVT) versus medical management in anterior circulation large vessel occlusion with large-core documented significant benefit of EVT on functional outcome. Moreover, one trial reported the benefit of EVT in the very large-core category (Alberta Stroke Program Early CT Score, 0-2). These results are considered paradoxical by some as they contradict the prevailing view that the presence of a large core precludes the possibility of good outcomes following reperfusion. They, in turn, led some investigators to question the applicability of the core/penumbra model in the case of large-core stroke and even its overall validity, specifically regarding the notion that the core reliably predicts tissue infarction. Here, we discuss the trial results and propose alternative explanations for the large-core paradox. First, although EVT does improve outcomes as compared with medical management, overall outcomes remain poor in ≈80% of the treated population. Second, the assessment of core extent on imaging, particularly with computed tomography, is potentially inaccurate, especially in the early time window. Third, consistent with observational studies, some randomized controlled trial substudies suggest that the benefit of EVT in this population derives at least in part from the salvage of penumbra, which appears to have been present in a large percentage of enrolled patients. Fourth, the markedly reduced perfusion that prevails within large cores facilitates the early development of vasogenic edema. This heterogeneity of tissue injury may, in turn, lead to an overestimation of true core/neuronal death as estimated with computed tomography and magnetic resonance imaging. Assessing patients with apparent large core should consider these notions when discussing eligibility for EVT. Early reperfusion of large-core patients is expected to both target any residual penumbra and prevent the development of vasogenic edema within the severely hypoperfused areas. These considerations underscore the need for more reliable methods to identify irreversible neuronal injury inside the imaging-based estimated core.

Keywords: brain edema; brain infarction; brain ischemia; endovascular procedures; perfusion imaging; stroke.

PubMed Disclaimer

Conflict of interest statement

Dr Seners reports compensation from Acticor for consultant services and compensation from Boehringer Ingelheim for other services. Dr Arquizan reports compensation from Amgen for other services and compensation from Medtronic Vascular, Inc, for other services. Dr Muir reports compensation from Boehringer Ingelheim, Woolsey Pharma, AbbVie, Brainomix, and Biogen for consultant services; compensation from IschemaView and Boehringer Ingelheim for other services; and employment by the University of Glasgow. Dr Saver reports compensation from Johnson & Johnson Health Care Systems, Inc, Stream Medical, CSL Behring, Boehringer Ingelheim (prevention only), BrainsGate, Bayer, Roche, Medtronic USA, Inc, Aeromics, Abbott Laboratories, BrainQ, and Biogen for consultant services; compensation from Occlutech and MIVI Neuroscience for data and safety monitoring services; and stock options in Neuronics Medical, Rapid Medical, and MindRhythm. Dr Albers reports compensation from Genentech and iSchemaView for consultant services and stock holdings in iSchemaView. Dr Costalat reports compensation from Stryker Corporation, Balt USA, LLC, MicroVention, Inc, Penumbra, Inc, Johnson & Johnson Health Care Systems, Inc, and Medtronic USA, Inc, for consultant services. Dr Baron reports employment by Sainte-Anne Hospital Paris and compensation from Frontiers in Neurology for other services. The other authors report no conflicts.